Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Current Assets (2019 - 2025)

Historic Current Assets for Eton Pharmaceuticals (ETON) over the last 7 years, with Q3 2025 value amounting to $72.0 million.

  • Eton Pharmaceuticals' Current Assets rose 14202.49% to $72.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.0 million, marking a year-over-year increase of 14202.49%. This contributed to the annual value of $41.0 million for FY2024, which is 5284.1% up from last year.
  • Per Eton Pharmaceuticals' latest filing, its Current Assets stood at $72.0 million for Q3 2025, which was up 14202.49% from $68.4 million recorded in Q2 2025.
  • Eton Pharmaceuticals' Current Assets' 5-year high stood at $72.0 million during Q3 2025, with a 5-year trough of $16.4 million in Q3 2022.
  • For the 5-year period, Eton Pharmaceuticals' Current Assets averaged around $31.3 million, with its median value being $26.3 million (2023).
  • In the last 5 years, Eton Pharmaceuticals' Current Assets tumbled by 3806.24% in 2022 and then surged by 16910.04% in 2025.
  • Over the past 5 years, Eton Pharmaceuticals' Current Assets (Quarter) stood at $23.6 million in 2021, then decreased by 15.25% to $20.0 million in 2022, then surged by 34.17% to $26.8 million in 2023, then soared by 52.84% to $41.0 million in 2024, then surged by 75.52% to $72.0 million in 2025.
  • Its last three reported values are $72.0 million in Q3 2025, $68.4 million for Q2 2025, and $50.0 million during Q1 2025.